Israel Lowy MD
Adjunct Assistant Clinical Professor, Medicine - Infectious Diseases,
Join to View Full Profile
42 Appleton PlDobbs Ferry, NY 10522
Phone+1 914-674-1146
Fax+1 914-674-0967
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Israel Lowy, MD is an infectious disease specialist in Dobbs Ferry, New York. He is currently licensed to practice medicine in New York. He is an Adjunct Assistant Clinical Professor at Medicine - Infectious Diseases,.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Infectious Disease, 1989 - 1990- New York Presbyterian Hospital (Columbia Campus)Fellowship, Infectious Disease, 1987 - 1988
- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1984 - 1987
Columbia University Vagelos College of Physicians and SurgeonsClass of 1984
Certifications & Licensure
NY State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 424 citationsCemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomis...Ahmet Sezer, Saadettin Kilickap, Mahmut Gumus, Igor Bondarenko, Mustafa Ozguroglu
Lancet. 2021-02-13 - 49 citationsACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediat...Andrew D.J. Pearson, Claudia Rossig, G. Lesa, Scott J. Diede, Susan L. Weiner
European Journal of Cancer. 2020-01-24 - 874 citationsPD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinomaMichael R. Migden, Danny Rischin, Chrysalyne D. Schmults, Alexander Guminski, Axel Hauschild
The New England Journal of Medicine. 2018-06-04
Press Mentions
Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (Cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient PopulationsMay 26th, 2023- Libtayo® (Cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-Line Treatment of Advanced PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)March 29th, 2023
- Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (Cemiplimab) in Multiple Solid Tumor TypesDecember 1st, 2022
- Join now to see all
